Bacteria-Enhanced Graphene Oxide Nanoparticles for Triple-Action Tumor Eradication
en-GBde-DEes-ESfr-FR

Bacteria-Enhanced Graphene Oxide Nanoparticles for Triple-Action Tumor Eradication


Researchers developed graphene oxide nanoparticles that combine chemotherapy, immune activation, and photothermal heating to effectively destroy tumors

Modern cancer treatments have evolved beyond traditional chemotherapy to include targeted approaches such as immunotherapy, radiation therapy, and photothermal therapy. Graphene oxide (GO), known for its biocompatibility, high photothermal conversion efficiency, and large surface area, has emerged as a promising material for both drug delivery and thermal-based tumor destruction. However, its clinical application remains limited due to challenges in dispersibility and large-scale production.

To overcome these limitations, Professor Eijiro Miyako and his research team from the Japan Advanced Institute of Science and Technology (JAIST) have developed a novel GO nanocomposite enhanced with bacterial components. This paper was made available online on March 21, 2025, and will be published in Volume 238, Issue 5 of the journal Carbon on May 5, 2025. The study highlights how bacterial properties improve GO’s effectiveness in cancer therapy. Certain bacteria naturally stimulate immune responses and enhance dispersibility of GO due to their amphiphilic cellular components.

Using this concept, the researchers designed a GO-based nanocomposite containing Cutibacterium acnes (CA) bacterial components and the chemotherapy drug camptothecin (CPT). These nanoparticles eradicate tumors through a three-pronged mechanism: bacterial components activate the immune system, CPT delivers localized chemotherapy, and GO facilitates photothermal therapy.

“CPT delivers localized chemotherapy, GO intensifies heat-based tumor destruction, and CA components activate immune defenses. Together, these effects provide a highly promising cancer treatment,” explains Dr. Miyako.

The nanocomposites were prepared by sonicating a mixture of GO, CA bacterial components, and CPT in a cell culture medium. The resulting particles, averaging 53 nm in size, were stabilized by a bacterial coating, improving their dispersibility and biological compatibility. When injected into mice with colorectal cancer, the nanoparticles preferentially accumulated in tumors while sparing other organs due to the enhanced permeability and retention effect. Even without laser activation, they effectively suppressed tumor growth by leveraging the combined effects of chemotherapy and immune activation.

Further enhancing treatment efficacy, the researchers applied a low-power laser (0.8 W) for five minutes, heating the tumors to 50 °C—enough to destroy cancer cells without harming healthy tissue. After five laser treatments, the mice showed complete tumor eradication and full recovery. Analysis using qPCR confirmed that immune cells, including T cells, B cells, neutrophils, macrophages, and natural killer cells, were activated, demonstrating a strong immune response driven by CA components.

Unlike conventional GO modification methods, which involve complex chemical processing, this bacterial-based approach offers a cost-effective and scalable alternative. “Cancer is a highly progressive and complex disease, requiring a multidimensional approach to fight it,” says Dr. Miyako. “The proposed approach is cost-effective, requires minimal resources, such as bacterial culture media, and is easily scalable for mass production via a simple single-step sonication process.”

This study presents a promising strategy for enhancing GO-based cancer therapies, providing a simple and scalable method for developing multifunctional nanoparticles with potent anti-cancer effects.


###

Reference
Title of original paper: Hybrid Nanoarchitectonics with Bacterial Component-Integrated Graphene Oxide for Cancer Photothermo-Chemo-Immunotherapy
Authors: Soudamini Chintalapati, Eijiro Miyako*
Journal: Carbon
DOI: 10.1016/j.carbon.2025.120252
Title: Hybrid Nanoarchitectonics with Bacterial Component-Integrated Graphene Oxide for Cancer Photothermo-Chemo-Immunotherapy
Authors: Soudamini Chintalapati, Eijiro Miyako*
Journal: Carbon
DOI: 10.1016/j.carbon.2025.120252
Funding information:
This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Scientific Research (A) (Grant number 23H00551), JSPS KAKENHI Grant-in-Aid for Challenging Research (Pioneering) (Grant number 22K18440), the Japan Science and Technology Agency (JST) for Adaptable and Seamless Technology Transfer Program through target-driven R&D (Grant Number JPMJTR22U1), and JST Program for co-creating startup ecosystem (Grant Number JPMJSF2318). We also thank Mr. Mitsuru Kawahara (JAIST) for his dedicated support for the animal experiments.
Attached files
  • Image title: Fabrication of graphene oxide nanocomposite by single-step sonification process.  Image caption: Schematic of the modified graphene oxide nanoparticle (right) illustrates the integration of a chemotherapy drug camptothecin (orange circle), a fluorescent dye (pink star), and bacterial coating of Cutibacterium acnes onto graphene oxide nanoparticle.  Image credit: Eijiro Miyako from JAIST.
Regions: Asia, Japan
Keywords: Science, Chemistry, Life Sciences, Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • BBC
  • The Times
  • National Geographic
  • University of Cambridge
  • iesResearch
Copyright 2025 by AlphaGalileo Terms Of Use Privacy Statement